Growth Disorders

31 December 2018
medwireNews: Most children continue on a normal growth trajectory if their recombinant human growth hormone (GH) dose is reduced by half after they have achieved catch-up growth, shows a randomised trial. Considering the long duration of GH treatment, “the ultimate goal” after children have achieved catch-up growth should be to use the lowest... Read More
30 November 2018
medwireNews: Adherence to recombinant human growth hormone (GH) has a strong influence on the growth response of children with GH deficiency, especially during the second year of treatment, report researchers. The findings emerge from an analysis of 95 prepubertal participants of the easypod Connect observational study (ECOS) who had complete... Read More
01 November 2018
medwireNews: Researchers have identified a novel mutation in the insulin-like growth factor (IGF)2 gene that they believe to be responsible for impaired pre- and postnatal growth in one of their patients. This finding “argues for the inclusion of IGF2 in gene panels designed for routine diagnostics of intrauterine growth failure... Read More
30 September 2018
medwireNews: Two reports from the GeNeSIS observational study reveal the latest growth data and confirm that the safety profile of recombinant human growth hormone (rhGH) “remains favourable”. However, Christopher Child (Eli Lilly and Company, Windlesham, UK) and study co-authors note in The Journal of Clinical Endocrinology &... Read More
31 August 2018
medwireNews: The SYNERGY trial investigators report significant improvements in height velocity in South Korean children with idiopathic short stature (ISS) treated with daily recombinant human growth hormone (rhGH). During the first 6 months of treatment, the average height velocity increased from 5.63 cm/year to 10.08 cm/year in 59 children... Read More
31 July 2018
medwireNews: Real-time data on treatment adherence show its importance for good growth outcomes in patients taking recombinant human growth hormone (GH). Ekaterina Koledova (Merck Serono SA, Darmstadt, Germany) and colleagues made use of data from 1190 patients in the easypod™ connect observational study (ECOS), a register of patients using... Read More